<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Clin Microbiol Antimicrob</journal-id><journal-title>Annals of Clinical Microbiology and Antimicrobials</journal-title><issn pub-type="epub">1476-0711</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19183459</article-id><article-id pub-id-type="pmc">2654859</article-id><article-id pub-id-type="publisher-id">1476-0711-8-4</article-id><article-id pub-id-type="doi">10.1186/1476-0711-8-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Abdelaal</surname><given-names>Amina</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Amina_abdelaal@yahoo.com</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>El-Ghaffar</surname><given-names>Hassan Abd</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>haabd_elghaffar@mans.edu.eg</email></contrib><contrib id="A3" corresp="yes" contrib-type="author"><name><surname>Zaghloul</surname><given-names>Mohammad Hosam Eldeen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hosam_z@yahoo.com</email></contrib><contrib id="A4" equal-contrib="yes" contrib-type="author"><name><surname>El mashad</surname><given-names>Noha</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>nmashad@hotmail.com</email></contrib><contrib id="A5" equal-contrib="yes" contrib-type="author"><name><surname>Badran</surname><given-names>Ehab</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ehabrkha@yahoo.com</email></contrib><contrib id="A6" equal-contrib="yes" contrib-type="author"><name><surname>Fathy</surname><given-names>Amal</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>ml_fthy@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Clinical pathology department, Faculty of Medicine, Mansoura University, Mansoura, Egypt</aff><aff id="I2"><label>2</label>Thoracic medicine department, Faculty of Medicine, Mansoura University, Mansoura, Egypt</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>30</day><month>1</month><year>2009</year></pub-date><volume>8</volume><fpage>4</fpage><lpage>4</lpage><ext-link ext-link-type="uri" xlink:href="http://www.ann-clinmicrob.com/content/8/1/4"/><history><date date-type="received"><day>18</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>30</day><month>1</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Abdelaal et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Abdelaal et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Abdelaal
               Amina
               
               Amina_abdelaal@yahoo.com
            </dc:author><dc:title>
            Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial
         </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Annals of Clinical Microbiology and Antimicrobials 8(1): 4-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-0711(2009)8:1&#x0003c;4&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-0711</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Tuberculosis is a growing international health concern. It is the biggest killer among the infectious diseases in the world today. Early detection of drug resistance allows starting of an appropriate treatment. Resistance to drugs is due to particular genomic mutations in specific genes of Mycobacterium tuberculosis(MTB). The aim of this study was to identify the presence of Isoniazid (INH) and Rifampicin(RIF) drug resistance in new and previously treated tuberculosis (TB) cases using DNA sequencing.</p></sec><sec sec-type="methods"><title>Methods</title><p>This study was carried out on 153 tuberculous patients with positive Bactec 460 culture for acid fast bacilli.</p></sec><sec><title>Results</title><p>Of the 153 patients, 105 (68.6%) were new cases and 48 (31.4%) were previously treated cases. Drug susceptibility testing on Bactec revealed 50 resistant cases for one or more of the first line antituberculous. Genotypic analysis was done only for rifampicin resistant specimens (23 cases) and INH resistant specimens (26 cases) to detect mutations responsible for drug resistance by PCR amplification of rpoB gene for rifampicin resistant cases and KatG gene for isoniazid resistant cases. Finally, DNA sequencing was done for detection of mutation within rpoB and KatG genes. Genotypic analysis of RIF resistant cases revealed that 20/23 cases (86.9%) of RIF resistance were having rpoB gene mutation versus 3 cases (13.1%) having no mutation with a high statistical significant difference between them (P &#x0003c; 0.001). Direct sequencing of Kat G gene revealed point mutation in 24/26 (92.3%) and the remaining 2/26 (7.7%) had wild type KatG i.e. no evidence of mutation with a high statistical significant difference between them (P &#x0003c; 0.001).</p></sec><sec><title>Conclusion</title><p>We can conclude that rifampicin resistance could be used as a useful surrogate marker for estimation of multidrug resistance. In addition, Genotypic method was superior to that of the traditional phenotypic method which is time-consuming taking several weeks or longer.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Tuberculosis is a growing international health concern. It is the biggest killer among the infectious diseases in the world today, despite the use of a live attenuated vaccine and several antibiotics. After years of decline, TB has re-emerged as a serious public health problem worldwide, especially with increased drug resistance among MTB strains which hinders the success of TB control programs[<xref ref-type="bibr" rid="B1">1</xref>]. Isolation, identification, and drug susceptibility testing of MTB and other clinically important mycobacteria can take several weeks because of its slow growth rate. During the past several years, many molecular methods have been developed which can potentially reduce the diagnostic time from weeks to hours. Early detection of drug resistance allows starting of appropriate treatment, which has an impact on better control of the disease[<xref ref-type="bibr" rid="B2">2</xref>]. Resistance to drugs is due to particular genomic mutations in specific genes of MTB. To date, nine genes are known to be linked to resistance to first-line anti-TB drugs; katG, inhA, aphC, and kasA for INH resistance, rpoB for RIF resistance, rpsL and rrs for strptomycin (STR) resistance, embB for ethambtol (EMB) resistance, and pncA for pyazinamid (PZA) resistance. Resistance to multiple drugs is the consequence of an accumulation of mutations[<xref ref-type="bibr" rid="B3">3</xref>]. RIF interferes with transcription and elongation of RNA by binding to the &#x003b2;-subunit of RNA polymerase. The rpoB gene encodes RNA polymerase enzyme of MTB. So, any mutation in 81 bp hypervariable region of the rpoB gene results in failure of binding and subsequently resistance[<xref ref-type="bibr" rid="B4">4</xref>]. The katG gene encodes mycobacterial catalase peroxidase which is the only enzyme in MTB capable of activating the pro-drug INH to active form. Furthermore, katG gene is involved in detoxification of endogenously generated or exogenously supplied hydrogen peroxide[<xref ref-type="bibr" rid="B5">5</xref>].</p><sec><title>Aim of the work</title><p>This study was designed to identify the presence of INH and RIF drug resistance in new and previously treated tuberculosis (TB) cases using DNA sequencing.</p></sec></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>This study was carried out on 153 tuberculous patients (83 males and 70 females) with positive Bactec 460 culture for acid fast bacilli. They were selected from Mansoura University Hospitals and Mansoura chest hospital. Drug susceptibility testing on Bactec revealed 50 resistant cases for one or more of the first line antituberculous (Isoniazid, rifampicin, ethambutol and streptomycin). All resistant TB cases were subjected to full history taking especially for past history of similar conditions, intake of antituberculous drugs, clinical and radiological examinations. They were 33 males and 17 females with their ages ranging from 19 to 52 years. Informed written consents were taken from all patients and the study was approved by the Ethics Committee of Mansoura University.</p></sec><sec><title>Definitions</title><p>Patients were classified into two groups according to their treatment history at the time of diagnosis: new cases, which included patients who had never received anti-TB treatment or who had received treatment for &#x0003c;4 weeks, and previously treated cases, which included patients who had taken anti-TB drugs for at least 4 weeks [<xref ref-type="bibr" rid="B6">6</xref>]. Initial resistance was defined as the presence of drug-resistant <italic>M. tuberculosis </italic>strains in new cases. Acquired resistance was defined as the presence of drug-resistant <italic>M. tuberculosis </italic>strains in patients who were reported to have received anti-TB treatment for &#x0003e;4 weeks. Mono resistance was defined as resistance to only one of the four first-line 8 drugs. Multidrug resistance (MDR) was defined as resistance to at least Isoniazid and rifampicine [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>].</p></sec><sec><title>Collection of the specimens</title><p>Three consecutive spontaneously produced early morning sputum samples were collected from patients with pulmonary TB. Samples were collected in sterile containers to avoid contamination with environmental bacteria e.g. Mycobacterium xenopi.</p></sec><sec><title>Laboratory methods</title><p>All resistant TB cases were subjected to detection of tubercle bacilli and anti-tuberculous drug susceptibility testing by radiometric method (BACTEC 460 system, Becton Dickinson microbiology Systems, Cockeysville, M.A. 21030, 800-638-8663).</p><p>Genotypic analysis was done only for rifampicin resistant specimens (23 cases) and INH resistant specimens (26 cases) to detect mutations responsible for drug resistance by PCR amplification of rpoB gene for rifampicin resistant cases and KatG gene for isoniazid resistant cases. Finally, DNA sequencing was done for detection of mutation within rpoB and KatG genes.</p></sec><sec><title>Molecular characterization of resistant strains</title><p>It included three main steps:</p><p>1-DNA extraction to release DNA from mycobacterial cells.</p><p>2-Amplification of the target part of gene by PCR and detection by agarose gel electrophoresis.</p><p>3-Automated DNA sequencing to detect mutation in comparison with the similar region of a wild strain[<xref ref-type="bibr" rid="B9">9</xref>].</p><sec><title>1-DNA extraction</title><p>QIAamp DNA Mini kit was used to purify total DNA from decontaminated sputum samples (Qiagen Inc. 28159 Avenue Stanford, Valencia, CA 91355. fax 800-718-2056, USA).</p></sec><sec><title>2-DNA amplification</title></sec></sec><sec><title>PCR amplification of rpoB &#x00026; KatG genes</title><p>A 157-bp fragment of the rpoB gene, from nucleotide 1846 to 2002 (Gen Bank accession no. <ext-link ext-link-type="gen" xlink:href="U12205">U12205</ext-link>) was amplified by using the primers TR9(TCGCCGCGATCAAGGAGT)and TR8(TGCACGTCGCGGACCTCCA). The 200-bp KatG fragment targetting codon 315 from nucleotide 904 to 1103 (Gen Bank accession no. <ext-link ext-link-type="gen" xlink:href="X68081">X68081</ext-link>) was amplified by using primers KatGIF(AGCTCGTATGGCACCGGAAC) and KatG4RB(AACGGGTCCGGGATGGTG).</p><p>Qiagen taq PCR Master (250 Unit): (2&#x000d7; concentrated, contains polymerase, PCR buffer with 3 mM MgCl<sub>2 </sub>and 400 mM of each dNTP).</p><sec><title>Procedure</title><p>Master mix was prepared as shown in Table <xref ref-type="table" rid="T1">1</xref>. The required volume for each sample was multiplied by the number of samples and adding a negative control plus one. The mixture was mixed by vortex and dispensed (50 ul) in each tube. PCR tubes were placed in the thermal cycler under the appropriate amplification conditions (Table <xref ref-type="table" rid="T2">2</xref>). Each PCR was preceded by a single denaturation step at 94&#x000b0;C for 4 min. and terminated with a single primer extension step at 72&#x000b0;C for 8 min. The last cycle was followed by cooling to 4&#x000b0;C and holding at this temperature until the tubes were taken out off the machine.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Amplification master mix</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Component</bold></td><td align="left"><bold>Volume/sample</bold></td></tr></thead><tbody><tr><td align="left">Sterile nuclease free water</td><td align="left">3 ul</td></tr><tr><td align="left">Forward primer</td><td align="left">6 ul</td></tr><tr><td align="left">Reverse Primer</td><td align="left">6 ul</td></tr><tr><td align="left">Master mix</td><td align="left">25 ul</td></tr><tr><td align="left">DNA template</td><td align="left">10 ul</td></tr><tr><td align="left">Final volume</td><td align="left">50 ul</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Amplification conditions.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene</bold></td><td align="left"><bold>Denaturation</bold></td><td align="left"><bold>Annealing</bold></td><td align="left"><bold>Extension</bold></td><td align="left"><bold>No. of cycles</bold></td></tr></thead><tbody><tr><td align="left">rpoB</td><td align="left">94&#x000b0;C, 1 min.</td><td align="left">55&#x000b0;C,1 min.</td><td align="left">72&#x000b0;C, 1 min.</td><td align="left">40 cycles</td></tr><tr><td align="left">Ka G</td><td align="left">94&#x000b0;C, 1 min.</td><td align="left">61&#x000b0;C, 1 min.</td><td align="left">72&#x000b0;C, 1 min.</td><td align="left">30 cycles</td></tr></tbody></table></table-wrap></sec><sec><title>3-DNA Sequencing</title><p>This was done by the use of ABI Prism 310 Genetic Analyzer (figure <xref ref-type="fig" rid="F1">1</xref>), (Applied Biosystems, Foster city, Calif., 944041 USA).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Sequencing reaction obtained from labeled amplified genes by ABI 310 Sequencer Analyzer</bold>.</p></caption><graphic xlink:href="1476-0711-8-4-1"/></fig></sec></sec><sec><title>Statistical analysis</title><p>Data entry and analysis were performed using SPSS statistical package for social science version 10 (SPSS, Inc., Chicago, IL, USA). The quantitative data were presented as a mean and standard deviation and the qualitative data were presented as number and percentage. The chi-square (&#x003c7;2) was used to find the association between row and column variables of qualitative data. The threshold of significance is fixed at 5% level (P value). P value of &#x0003e; 0.05 indicates non-significant results; P value of &#x0003c; 0.05 indicates a significant result while, P value of &#x0003c; 0.001 indicates a high significant result.</p></sec></sec><sec><title>Discussion</title><p>Tuberculosis, one of the oldest recorded human diseases, is still one of the biggest killers among the infectious diseases, despite the use of a live attenuated vaccine and several antibiotics. The development of drug resistance in the population has increased the possibility that TB may once again become an incurable disease[<xref ref-type="bibr" rid="B10">10</xref>]. Resistance to drugs is due to particular genomic mutations in specific genes of <italic>MTB</italic>. To date, nine genes are known to be linked to resistance to first-line anti-TB drugs; <italic>katG, inhA, aphC</italic>, and <italic>kasA </italic>for INH resistance, <italic>rpoB </italic>for RIF resistance, <italic>rpsL </italic>and <italic>rrs </italic>for STR resistance, <italic>embB </italic>for EMB resistance, and <italic>pncA </italic>for PZA resistance. Resistance to multiple drugs is the consequence of an accumulation of mutations[<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Because the organism is slow growing, traditional determination of resistance is time-consuming as it may take several weeks or longer. Rapid detection of drug resistance could optimize treatment, improve outcome for patients with drug-resistant tuberculosis and prevent transmission of drug-resistant TB. Genotypic methods have the advantage of a shorter turnaround time, no need for growth of the organism, possibility for direct application in clinical samples, less biohazard risks, and feasibility for automation [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Therefore, the aim of this study was to identify the presence of INH and RIF drug resistance in new and previously treated tuberculosis (TB) cases using DNA sequencing. To achieve this aim, 153 tuberculous patients with cultures positive for acid fast bacilli were selected from Mansoura University and Chest Hospitals (Table <xref ref-type="table" rid="T3">3</xref>). Out of 153 tuberculous patients, 50 resistant cases to one or more of the first line antituberculous drugs (isoniazid, rifampicine, ethambutol and streptomycin) were selected after drug susceptibility testing by BACTEC 460. All of them were identified by NAP test as Mycobacterium tuberculosis complex. They were 33 males and 17 females with their ages ranging from 19 to 52 years. From 50 resistant cases, genotypic analysis was done only for 23 rifampicine resistant cases (rpoB gene) and 26 isoniazid resistant cases (KatG gene) to detect mutation responsible for drug resistance by automated DNA sequencer (ABI Prism 310 Genetic Analyzer).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Characteristics of the study population (n = 153)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Mean age, years (range)</bold></td><td align="left"><bold>38 (19&#x02013;52)</bold></td></tr></thead><tbody><tr><td align="left">Male patients</td><td align="left">83 (54.3%)</td></tr><tr><td align="left">Female patients</td><td align="left">70 (45.7%)</td></tr><tr><td align="left">Urban</td><td align="left">58 (38%)</td></tr><tr><td align="left">Rural</td><td align="left">97 (62 %)</td></tr><tr><td align="left">Previous TB treatment</td><td align="left">48 (31.4%)</td></tr><tr><td align="left">New cases</td><td align="left">105 (68.6%)</td></tr><tr><td align="left">Susceptible TB cases</td><td align="left">103(67.3%)</td></tr><tr><td align="left">Resistant TB cases</td><td align="left">50(32.7%)</td></tr></tbody></table></table-wrap><p>The rate of drug resistance (table <xref ref-type="table" rid="T4">4</xref>) was 32.7% (50/153 cases), with a higher prevalence of resistance in patients who had received previous anti-tuberculous treatment (70 %) than new patients (30%). This was in accordance with those reported in Saudi Arabia by Al-Hajjaj et al [<xref ref-type="bibr" rid="B11">11</xref>] that was 29.7% of 101 MTB isolates. However, a higher prevalence of resistance was found in Russia by Toungoussova et al.[<xref ref-type="bibr" rid="B12">12</xref>] that was 56.3% among 119 MTB isolates. Also, in Greece, Tarkada et al.[<xref ref-type="bibr" rid="B13">13</xref>] found 51.2% of 207 initial isolates of MTB. While a lower prevalence of resistance was reported by Rivera et al.[<xref ref-type="bibr" rid="B14">14</xref>] who studied 188 MTB in Philippines and noted that drug-resistance represented 17.6% of isolates. And in Qatar, by <italic>Al-Marri </italic>[<xref ref-type="bibr" rid="B15">15</xref>] who found 61(15%) among 406 MTB isolates. This low prevalence of resistance to four anti-tuberculous drugs may be due to screening programs (chest radiography) and implementation of directly observed therapy, short course(DOTS).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Previous anti-TB treatment in 50 resistant TB cases</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left">Resistant TB cases (50)</td><td></td></tr><tr><td></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td align="left">No</td><td align="left">%</td></tr></thead><tbody><tr><td align="left">Previous anti-TB treatment(Secondary resistance)</td><td align="left">35</td><td align="left">70</td></tr><tr><td align="left">No previous treatment (Primary resistance)</td><td align="left">15</td><td align="left">30</td></tr></tbody></table></table-wrap><p>Regarding prevalence of primary and secondary resistance, there was a higher prevalence of resistance in patients who received previous antituberculous treatment (70%) than patients with no previous treatment (30%). These results are fully consistent with other reports [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>] stating that resistance was significantly higher in previously treated cases (71%, 63%, and 95%; respectively) than in new cases.</p><p>Antituberculous drug susceptibility testing by BACTEC system in the present study (table <xref ref-type="table" rid="T5">5</xref>) revealed that INH had the highest resistance (52%), followed by Rifampicine (46%), Ethambutol (44%) and the lowest resistance was encountered with Streptomycin (36%). Also, Dawood [<xref ref-type="bibr" rid="B18">18</xref>] found that the drug resistance in TB cases were; 73 %, 63 %, 27 % and zero % to INH, Streptomycin, RIF and ETH; respectively. On the other hand, Annelies et al.[<xref ref-type="bibr" rid="B3">3</xref>] reported that resistance was 93%, 56%, 41% and 18% to INH, RIF, STR and EMB; respectively. The significant increase in rifampicin, INH and ethambutol resistance in the last 10 years could be attributed to poor compliance and wide use of these drugs for non-tuberculosis conditions. While, the high sensitivity of streptomycin was attributed to the restriction of its use in the management of tuberculous patients[<xref ref-type="bibr" rid="B18">18</xref>]. Furthermore, it could be noticed that the association of RIF resistance with other drugs (table <xref ref-type="table" rid="T6">6</xref>, <xref ref-type="table" rid="T7">7</xref>) was significantly higher 17/50 (34%) than RIF resistance alone 6/50 (12%). On the other hand, the association of INH resistance with other drugs 16/50 (32%) and INH resistance alone 10/50 cases (20%) was insignificant (P &#x0003e; 0.05). Similar results were found in 1999 by Narar et al.[<xref ref-type="bibr" rid="B19">19</xref>] who noted statistical significant difference between resistance to RIF only (5%) and resistant to RIF in association with other drugs (32.5%). So, Albert et al. [<xref ref-type="bibr" rid="B20">20</xref>] stated that rifampicine resistance has been identified as a useful surrogate marker for estimation of multidrug resistance and indicated that the second line drugs are urgently required.</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Drug susceptibility testing of resistant TB cases by BACTEC (50 cases)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Antituberculous drug</bold></td><td align="center" colspan="2"><bold>Sensitive</bold></td><td align="center" colspan="2"><bold>Resistant</bold></td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center">No</td><td align="center">%</td><td align="center">No</td><td align="center">%</td></tr></thead><tbody><tr><td align="left">Streptomycin</td><td align="center">32/50</td><td align="center">64%</td><td align="center">18/50</td><td align="center">36%</td></tr><tr><td align="left">INH</td><td align="center">24/50</td><td align="center">48%</td><td align="center">26/50</td><td align="center">52%</td></tr><tr><td align="left">Rifampicine</td><td align="center">27/50</td><td align="center">54%</td><td align="center">23/50</td><td align="center">46%</td></tr><tr><td align="left">Ethambutol</td><td align="center">28/50</td><td align="center">56%</td><td align="center">22/50</td><td align="center">44%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Phenotypic resistance pattern among RIF&#x00026;INH resistant cases</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Phenotypic resistance pattern</bold></td><td align="left"><bold>No</bold></td><td align="left"><bold>%</bold></td><td align="left"><bold>X2</bold></td><td align="left"><bold>P</bold></td></tr><tr><td></td><td></td><td></td><td colspan="2"><hr></hr></td></tr><tr><td align="left">RIF resistance alone (Monoresistance)</td><td align="left">6/50</td><td align="left">12%</td><td></td><td></td></tr></thead><tbody><tr><td align="left">RIF resistance with other drugs (Multidrug resistance)</td><td align="left">17/50</td><td align="left">34%</td><td align="left">0.526</td><td align="left">0.022*</td></tr><tr><td colspan="1"><hr></hr></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">INH resistance alone (Monoresistance)</td><td align="left">10/50</td><td align="left">20%</td><td align="left">1.38</td><td align="left">0.239</td></tr><tr><td colspan="1"><hr></hr></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">INH resistance with other drugs(Multidrug resistance)</td><td align="left">16/50</td><td align="left">32%</td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>&#x02022; P value of &#x0003c; 0.05 is significant.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T7"><label>Table 7</label><caption><p>Different association of drug resistance in studied resistant cases.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Type of resistance</bold></td><td align="center" colspan="2"><bold>Resistant cases(50)</bold></td></tr><tr><td></td><td align="center"><bold>No</bold></td><td align="center"><bold>%</bold></td></tr></thead><tbody><tr><td align="left"><bold><italic>One drug resistance</italic></bold></td><td align="center"><bold><italic>24</italic></bold></td><td align="center"><bold><italic>46</italic></bold></td></tr><tr><td align="left">&#x02003;<italic>RIF</italic></td><td align="center">6</td><td align="center">12</td></tr><tr><td align="left">&#x02003;<italic>INH</italic></td><td align="center">10</td><td align="center">20</td></tr><tr><td align="left">&#x02003;<italic>SM</italic></td><td align="center">4</td><td align="center">8</td></tr><tr><td align="left">&#x02003;<italic>EMB</italic></td><td align="center">4</td><td align="center">8</td></tr><tr><td align="left"><bold><italic>Two drug resistance</italic></bold></td><td align="center"><bold><italic>16</italic></bold></td><td align="center"><bold><italic>32</italic></bold></td></tr><tr><td align="left">&#x02003;<italic>RIF+INH</italic></td><td align="center">5</td><td align="center">10</td></tr><tr><td align="left">&#x02003;<italic>RIF+EMB</italic></td><td align="center">2</td><td align="center">4</td></tr><tr><td align="left">&#x02003;<italic>INH+SM</italic></td><td align="center">1</td><td align="center">2</td></tr><tr><td align="left">&#x02003;<italic>INH+EMB</italic></td><td align="center">2</td><td align="center">4</td></tr><tr><td align="left">&#x02003;<italic>SM+EMB</italic></td><td align="center">6</td><td align="center">12</td></tr><tr><td align="left"><bold><italic>Three drug resistance</italic></bold></td><td align="center"><bold><italic>7</italic></bold></td><td align="center"><bold><italic>14</italic></bold></td></tr><tr><td align="left">&#x02003;<italic>RIF+INH+SM</italic></td><td align="center">2</td><td align="center">4</td></tr><tr><td align="left">&#x02003;<italic>RIF+INH+EMB</italic></td><td align="center">3</td><td align="center">6</td></tr><tr><td align="left">&#x02003;<italic>RIF+ SM+EMB</italic></td><td align="center">2</td><td align="center">4</td></tr><tr><td align="left"><bold><italic>Four drug resistance</italic></bold></td><td></td><td></td></tr><tr><td align="left">&#x02003;<italic>RIF+INH+EMB+SM</italic></td><td align="center"><bold><italic>3</italic></bold></td><td align="center"><bold><italic>6</italic></bold></td></tr></tbody></table></table-wrap><p>Genotypic analysis of RIF resistant cases (table <xref ref-type="table" rid="T8">8</xref>) revealed that 20/23 cases (86.9%) showed rpoB gene mutation versus 3 cases (13.1%) having no mutation. A discrepancy between the results of the phenotypic and genotypic drug resistance tests (absence of mutation in 13.1% of phenotypically resistant isolate) could be attributed to the presence of other mutations located either outside the selected target regions (codon position) or outside the selected gene itself (<italic>rpoB </italic>gene). Another explanation was the so called "heteroresistance" that means the presence of mixture of susceptible and resistant subpopulation in culture which could be an obstacle against the sensitivity of molecular drug resistance testing and the successive therapy[<xref ref-type="bibr" rid="B21">21</xref>].</p><table-wrap position="float" id="T8"><label>Table 8</label><caption><p>Frequency of mutations among RIF resistant cases (rpo B gene) &#x00026; INH resistant cases (KatG gene)</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>Mutation</bold></td><td align="left"><bold>No mutation</bold></td><td align="left"><bold>Total</bold></td><td align="left"><bold>X2</bold></td><td align="left"><bold>P</bold></td></tr></thead><tbody><tr><td align="left">RIF resistant cases (rpo B)</td><td align="left">20 (86.9%)</td><td align="left">3 (13.1%)</td><td align="left">23(100%)</td><td align="left">12.56</td><td align="left">&#x0003c;0.001</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">INH resistant cases (Kat G)</td><td align="left">24 (92.3%)</td><td align="left">2 (7.7%)</td><td align="left">26(100%)</td><td align="left">18.16</td><td align="left">&#x0003c;0.001</td></tr></tbody></table></table-wrap><p>The commonest point mutation (table <xref ref-type="table" rid="T9">9</xref> &#x00026; figure <xref ref-type="fig" rid="F2">2</xref>) was found at codon 531 in 9/20 (45%) with serine--&#x0003e;leucine substitution (TCG--&#x0003e;TTG). The second type of mutation was detected at codon 526 in 6/20 (30%) with histidine --&#x0003e;aspartate substitution (CAC--&#x0003e;GAC), followed by codon 516 in 4/20 (20%) with aspartate--&#x0003e; valine substitution (GAC--&#x0003e;GTC). The lowest point mutation was found at codon 522 in 1/20 (5%) with serine--&#x0003e; leucine substitution (TCG--&#x0003e;TTG). These results were similar to Kim et al.[<xref ref-type="bibr" rid="B22">22</xref>] in Korea, who found high-mutation frequencies of codon 526 (37.8%) and codon 531 (24.4%) in rifampin-resistant strains. Also, these findings were more or less in agreement with those results of the United States[<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>], Japan[<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>], Australia[<xref ref-type="bibr" rid="B27">27</xref>], Asia [<xref ref-type="bibr" rid="B28">28</xref>]Brazil and France,[<xref ref-type="bibr" rid="B29">29</xref>] China,[<xref ref-type="bibr" rid="B30">30</xref>] and in Netherlands[<xref ref-type="bibr" rid="B31">31</xref>].</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>rpoB gene mutations detected by DNA sequencing in RIF resistant cases</bold>.</p></caption><graphic xlink:href="1476-0711-8-4-2"/></fig><table-wrap position="float" id="T9"><label>Table 9</label><caption><p>Identification and location of mutation of rpoB gene (20) in RIF resistant cases, and of KatG gene (24) in INH resistant cases</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Mutated gene Codon</bold></td><td align="left"><bold>Nucleotide Substitution</bold></td><td align="left"><bold>Amino acid change</bold></td><td align="center" colspan="2"><bold>Mutation</bold></td></tr></thead><tbody><tr><td align="left"><bold>Mutated rpoB (20)</bold></td><td></td><td></td><td align="left">No</td><td align="left">%</td></tr><tr><td align="left">Codon 516</td><td align="left">GAC --&#x0003e; GTC</td><td align="left">Aspartate --&#x0003e;Valine</td><td align="left">4</td><td align="left">20</td></tr><tr><td align="left">Codon 522</td><td align="left">TCG --&#x0003e; TTG</td><td align="left">Serine --&#x0003e;Leucine</td><td align="left">1</td><td align="left">5</td></tr><tr><td align="left">Codon 526</td><td align="left">CAC --&#x0003e; GAC</td><td align="left">Histidine --&#x0003e;Aspartate</td><td align="left">6</td><td align="left">30</td></tr><tr><td align="left">Codon 531</td><td align="left">TCG --&#x0003e; TTG</td><td align="left">Serine --&#x0003e;Leucine</td><td align="left">9</td><td align="left">45</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Mutated KatG (24)</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Codon 315</td><td align="left">AGC --&#x0003e; ACC</td><td align="left">Serine --&#x0003e;Threonine</td><td align="left">24</td><td align="left">100</td></tr></tbody></table></table-wrap><p>In other similar studies in accordance to our data; Khamis et al.[<xref ref-type="bibr" rid="B32">32</xref>] found ten out of the eleven rifampicin resistant specimens (90.9%) showing gene mutation versus only one (9.1%) with no mutation. Point mutations was at codon 516 in 4/10 (40%) with aspargine &#x02192; valine substitution (CAG &#x02192; CTG). The second type of mutation was detected at codon 526 in 2/10 (20%) with histidine (H) &#x02192; tyrosine (Y) substitution (CAC&#x02192;GAC) and the last mutation was at codone 531 in 4/10 (40%) with serine (S) &#x02192;leucine (L) substitution (TCG &#x02192;TTG). Isfahani et al [<xref ref-type="bibr" rid="B4">4</xref>] in Iran analyzed 21 RIF resistant isolates and found point mutation in the 81-bp region of the rpoB gene in 18 strains (85.7%) and 3 strains (14.3%) had no mutations. The commonest point mutation was found at codon 531 in 10 cases (47.5%) with serine--&#x0003e;leucine substitution, followed by codon 526 in 4 cases (19.1%) with histidine --&#x0003e; aspargine substitution and codon 516 in one case (4.75%) with aspargine --&#x0003e; valine substitution.</p><p>On the other hand, in contrast to the above mentioned studies, Heep et al.[<xref ref-type="bibr" rid="B21">21</xref>] had shown a total mutations of 100% at completely unique codon positions apart from codon position mentioned in our study and other studies at codons 176, 441, 451 and 456. This indicates continuous emergence of new codon mutations every now and then.</p><p>Direct sequencing of KatG gene revealed point mutation in 24/26 (92.3%) and the remaining 2/26 (7.7%) had wild type KatG (no evidence of mutation) with high statistical significant difference between them (P &#x0003c; 0.001). Point mutation was found only at codon 315 (figure <xref ref-type="fig" rid="F3">3</xref>) in 24/24 (100%) with serine ---&#x0003e;threonine substitution (AGC--&#x0003e;ACC). Our results had supported the hypothesis of linking <italic>katG </italic>gene mutation to the development of INH resistance in MTB. The <italic>katG </italic>gene encodes mycobacterial catalase peroxidase which is the only enzyme in MTB capable of activating the pro-drug INH to active form. Furthermore, <italic>katG </italic>gene is involved in detoxification of endogenously generated or exogenously supplied hydrogen peroxide[<xref ref-type="bibr" rid="B5">5</xref>]. The absence of mutation in 7.7% of resistant isolates could be attributed to possible involvement of other codon positions at the same gene or other genes rather than the studied <italic>katG</italic>.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Identification and location of mutation of KatG gene detected by DNA Sequencing in INH resistant cases</bold>.</p></caption><graphic xlink:href="1476-0711-8-4-3"/></fig><p>Our data are in concordance with those reported in the Netherlands by Van Soolingen et al.[<xref ref-type="bibr" rid="B31">31</xref>], in Northwestern Russia by Mokrousov et al.[<xref ref-type="bibr" rid="B33">33</xref>], in China by Huo and Ge[<xref ref-type="bibr" rid="B34">34</xref>], in Lithuania by Bakonyte et al.[<xref ref-type="bibr" rid="B17">17</xref>], and in Germany by Hillemann et al [<xref ref-type="bibr" rid="B2">2</xref>] who analyzed 103 multidrug-resistant and 40 fully susceptible strains where mutation in <italic>katG </italic>codon 315 was detected in 91 of the 103 MDR strains (88.4%)with (AGC--&#x0003e;ACC) substitution and none of the 40 susceptible strains had mutations.</p><p>On the contrary, in Finland, a low prevalence of mutations in codon 315 was detected by Martilla et al.[<xref ref-type="bibr" rid="B35">35</xref>] who examined 54 INH-resistant isolates and found 100% katG point mutation with 7.5% only had codon 315 substitution and the remaining mutation positions were at other codons rather than 315. In addition, Ahmad et al.[<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>] found that mutation in codon 315 was detected in 18 (64%) out of 28 isoniazid-resistant isolates from Dubai and in six (35%) out of 17 resistant strains from Beirut. None of the susceptible strains contained this mutation. The genotyping studies showed that the majority of the isolates carrying AGC--&#x0003e;ACC substitution.</p></sec><sec><title>Conclusion</title><p>From the previous results, the currently available molecular methods are designed to determine the expected mutations within specific codons of the rpoB and katG genes. Therefore, although the molecular methods may aid in the rapid detection of mutations associated with drug resistance, there are major limitations to the molecular genetic detection of drug resistance; it detects only mutations that are screened for, while phenotypic tests detect resistance independent of the underlying mechanism and not all mutations conferring resistance to anti-TB drugs are known. This fact is especially a problem in the detection of INH resistance because of multiple genes involved. In addition, only few mutations conferring resistance to second-line drugs are known[<xref ref-type="bibr" rid="B30">30</xref>].</p><p>In summary, rifampicin resistance could be used as a useful surrogate marker for estimation of multidrug resistance and the second line drugs are urgently required. In addition, genotypic method was superior to that of the traditional phenotypic method which is time-consuming taking several weeks or longer. Moreover, the molecular technique, automated DNA sequencing, inspite of its high cost is of value in rapid detection of drug resistance (8 hours) resulting in improving the ability of clinicians to optimize early therapy. It has the advantage of a shorter turnaround time, no need for growth of the organism, possibility for direct application in clinical samples, can detect few numbers of bacilli, less biohazard risks and feasibility for automation. However, Further studies are needed using the automated DNA sequencing technique to identify other codon mutations associated with resistance to other anti-tuberculous drugs to obtain a standardized drug resistance data in Egypt.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>AAA is the one who suggested the idea and participated in the design of the study. HAG, MHZ, NM and EB carried out the molecular biology study and helped to draft the manuscript. AF was responsible for the choice of cases and the clinical data consultation. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We acknowledge all technicians who contributed towards the study by making the practical part of the study. We also acknowledge the team that was responsible for the statistics, acquisition of data. Also we should acknowledge persons who was involved in drafting the manuscript or revising it critically. The funding of the whole work was provided by the Mansoura faculty of medicine. Also we acknowledge anyone who contributed materials essential for the study.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palomino</surname><given-names>JC</given-names></name></person-group><article-title>Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis</article-title><source>Curr Opin Pulm Med</source><year>2006</year><volume>12</volume><fpage>172</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16582671</pub-id><pub-id pub-id-type="doi">10.1097/01.mcp.0000219265.50310.9b</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hillemann</surname><given-names>D</given-names></name><name><surname>Weizenegger</surname><given-names>M</given-names></name><name><surname>Kubica</surname><given-names>T</given-names></name><name><surname>Richter</surname><given-names>E</given-names></name><name><surname>Niemann</surname><given-names>S</given-names></name></person-group><article-title>Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates</article-title><source>J Clin Microbiol</source><year>2005</year><volume>43</volume><fpage>3699</fpage><lpage>3703</lpage><pub-id pub-id-type="pmid">16081898</pub-id><pub-id pub-id-type="doi">10.1128/JCM.43.8.3699-3703.2005</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Annelies</surname><given-names>VR</given-names></name><name><surname>Warren</surname><given-names>R</given-names></name><name><surname>Mshanga</surname><given-names>I</given-names></name><name><surname>Jordaan</surname><given-names>AM</given-names></name><name><surname>Spuy</surname><given-names>GD</given-names></name><name><surname>Richardson</surname><given-names>M</given-names></name><name><surname>Simpson</surname><given-names>J</given-names></name><name><surname>Gie</surname><given-names>RP</given-names></name><name><surname>Enarson</surname><given-names>DA</given-names></name><name><surname>Beyers</surname><given-names>N</given-names></name><name><surname>van Helden</surname><given-names>PD</given-names></name><name><surname>Victor</surname><given-names>TC</given-names></name></person-group><article-title>Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community</article-title><source>J Clin Microbiol</source><year>2001</year><volume>39</volume><fpage>636</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">11158121</pub-id><pub-id pub-id-type="doi">10.1128/JCM.39.2.636-641.2001</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isfahan</surname><given-names>BN</given-names></name><name><surname>Tavakoli</surname><given-names>A</given-names></name><name><surname>Salehi</surname><given-names>M</given-names></name><name><surname>Tazhibi</surname><given-names>M</given-names></name></person-group><article-title>Detection of rifampin resistance patterns in Mycobacterium tuberculosis strains isolated in Iran by polymerase chain reaction-single-strand conformation polymorphism and direct sequencing methods</article-title><source>Mem Inst Oswaldo Cruz</source><year>2006</year><volume>101</volume><fpage>597</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">17072470</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>LV</given-names></name><name><surname>Brown</surname><given-names>TJ</given-names></name><name><surname>Maxwell</surname><given-names>O</given-names></name><name><surname>Gibson</surname><given-names>AL</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Yates</surname><given-names>MD</given-names></name><name><surname>Drobniewski</surname><given-names>FA</given-names></name></person-group><article-title>Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpC-46A polymorphism</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><fpage>1455</fpage><lpage>1464</lpage><pub-id pub-id-type="pmid">15793126</pub-id><pub-id pub-id-type="doi">10.1128/AAC.49.4.1455-1464.2005</pub-id></citation></ref><ref id="B6"><citation citation-type="book"><person-group person-group-type="author"><collab>National Tuberculosis Control Program of Egypt</collab></person-group><article-title>Ministry of Health and Population management of tuberculosis</article-title><source>Training for health facility staff</source><publisher-name>Coated from World Health Organization training modules</publisher-name></citation></ref><ref id="B7"><citation citation-type="other"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Guidelines for the programmatic management of drug-resistant tuberculosis</article-title><source>Geneva: The Organization; Document no WHO/HTM/TB/2006361</source></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><collab>American Thoracic Society</collab></person-group><article-title>Diagnostic standards and classification of tuberculosis in adults and children</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>161</volume><fpage>1376</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">10764337</pub-id></citation></ref><ref id="B9"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>SK</given-names></name><name><surname>Mohan</surname><given-names>A</given-names></name></person-group><article-title>Multidrug-resistant tuberculosis</article-title><source>Indian J Med Re</source><year>2004</year><fpage>354</fpage><lpage>376</lpage></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>I</given-names></name></person-group><article-title>Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence</article-title><source>Clinic Microbiol Reviews</source><year>2003</year><volume>3</volume><fpage>463</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1128/CMR.16.3.463-496.2003</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>AL-Hajjaj</surname><given-names>MS</given-names></name><name><surname>AL-Kassimi</surname><given-names>FA</given-names></name><name><surname>AL-Mobeireek</surname><given-names>AF</given-names></name><name><surname>Alzeer</surname><given-names>AH</given-names></name></person-group><article-title>Progressive rise of Mycobacterium tuberculosis resistance to rifampicine and streptomycin in Riyadh, Saudi Arabia</article-title><source>Respirology</source><year>2001</year><volume>6</volume><fpage>317</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">11844123</pub-id><pub-id pub-id-type="doi">10.1046/j.1440-1843.2001.00344.x</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toungoussova</surname><given-names>S</given-names></name><name><surname>Caugant</surname><given-names>DA</given-names></name><name><surname>Sandven</surname><given-names>P</given-names></name><name><surname>Mariandyshev</surname><given-names>AO</given-names></name><name><surname>Bjune</surname><given-names>G</given-names></name></person-group><article-title>Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia</article-title><source>Int J Tuberc Lung Di</source><year>2002</year><volume>6</volume><fpage>406</fpage><lpage>14</lpage></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tarakada</surname><given-names>G</given-names></name><name><surname>Tsiamita</surname><given-names>M</given-names></name><name><surname>Spiropoulos</surname><given-names>K</given-names></name></person-group><article-title>Drug resistance of Mycobacterium Tuberculosis in Patras, Greece</article-title><source>Monaldi Arch Chest Dis</source><year>2004</year><volume>16</volume><fpage>65</fpage><lpage>70</lpage></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>AB</given-names></name><name><surname>Tupasi</surname><given-names>TE</given-names></name><name><surname>Balagtas</surname><given-names>ED</given-names></name><name><surname>Cardano</surname><given-names>RC</given-names></name><name><surname>Baello</surname><given-names>BQ</given-names></name><etal></etal></person-group><article-title>Drug resistance tuberculosis in the Philippines</article-title><source>Int J Tuber Lung Dis</source><year>1999</year><volume>3</volume><fpage>639</fpage></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Marri</surname><given-names>MR</given-names></name></person-group><article-title>Pattern of mycobacterial resistance to four anti-tuberculosis drugs in pulmonary tuberculosis drugs in pulmonary tuberculosis pateints in the state of Qatar after the implementation of DOTS and a limited expatriate screening programmes</article-title><source>Int J of Tuberc and lung Dis</source><year>2001</year><volume>5</volume><fpage>1116</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">11769769</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Del-Valle</surname><given-names>MB</given-names></name><name><surname>Ponce de-Leon</surname><given-names>A</given-names></name><name><surname>Arenas-Huertero</surname><given-names>C</given-names></name><name><surname>Vargas-Alarcon</surname><given-names>G</given-names></name><name><surname>Kato-Maeda</surname><given-names>M</given-names></name><name><surname>Small</surname><given-names>PM</given-names></name><name><surname>Couary</surname><given-names>P</given-names></name><name><surname>Ruiz-Palacios</surname><given-names>GM</given-names></name><name><surname>Sifuentes-Osornio</surname><given-names>J</given-names></name></person-group><article-title>rpoB gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-stranded conformational polymorphism</article-title><source>Emerg Infect Dis</source><year>2001</year><volume>7</volume><fpage>1010</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">11747730</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bakonyte</surname><given-names>D</given-names></name><name><surname>Baranauskaite</surname><given-names>A</given-names></name><name><surname>Cicenaite</surname><given-names>J</given-names></name><name><surname>Sosnovskaja</surname><given-names>A</given-names></name><name><surname>Stakenas</surname><given-names>P</given-names></name></person-group><article-title>Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania. Antimicrob</article-title><source>Agents Chemother Dis</source><year>2002</year><volume>47</volume><fpage>2009</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1128/AAC.47.6.2009-2011.2003</pub-id></citation></ref><ref id="B18"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Dawood</surname><given-names>AM</given-names></name></person-group><article-title>Value of modern microbiological technique in diagnosis of renal TB. Master degree thesis</article-title><source>Fac Med</source><year>2000</year><publisher-name>Mansoura University</publisher-name></citation></ref><ref id="B19"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Nawar</surname><given-names>NN</given-names></name><name><surname>Gad</surname><given-names>WH</given-names></name><name><surname>Ansary</surname><given-names>M</given-names></name><name><surname>Wassef</surname><given-names>MA</given-names></name></person-group><article-title>Evaluation of utility of molecular techniques for diagnosing multidrug resistant tuberculosis</article-title><source>MD Thesis in Clinical Pathology, Faculty of Medicine</source><year>1999</year><publisher-name>Cairo University</publisher-name></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>H</given-names></name><name><surname>Heydenrych</surname><given-names>A</given-names></name><name><surname>Brookes</surname><given-names>R</given-names></name><name><surname>Mole</surname><given-names>RJ</given-names></name><name><surname>Harley</surname><given-names>B</given-names></name><name><surname>Subotsky</surname><given-names>E</given-names></name><name><surname>Henry</surname><given-names>R</given-names></name><name><surname>Azevedo</surname><given-names>V</given-names></name></person-group><article-title>Performance of a rapid phage-based test, FAST plaque TB-RIF TM, to diagnose pulmonary tuberculosis from sputum specimens in South Africa</article-title><source>Int J Tuberc Lung Dis</source><year>2002</year><fpage>529</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">12068987</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heep</surname><given-names>M</given-names></name><name><surname>Brandster</surname><given-names>B</given-names></name><name><surname>Rieger</surname><given-names>U</given-names></name><name><surname>Lehn</surname><given-names>N</given-names></name><name><surname>Richter</surname><given-names>E</given-names></name><name><surname>Niemann</surname><given-names>S</given-names></name></person-group><article-title>Frequency of rpoB mutations inside and outside the cluster I region in rifampicine-resistant clinical Mycobacterium tuberculosis isolates</article-title><source>J Clin Microbiol</source><year>2001</year><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">11136757</pub-id><pub-id pub-id-type="doi">10.1128/JCM.39.1.107-110.2001</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BJ</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Lyu</surname><given-names>ME</given-names></name><name><surname>Park</surname><given-names>IK</given-names></name><name><surname>Bai</surname><given-names>GH</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Cha</surname><given-names>CY</given-names></name><name><surname>Kook</surname><given-names>YH</given-names></name></person-group><article-title>Mutations in the rpoB gene of Mycobacterium tuberculosis that interfere with PCR-single-Strand conformation polymorphism analysis for rifampin susceptibility testing</article-title><source>J Clin Microb</source><year>1997</year><volume>35</volume><fpage>492</fpage><lpage>494</lpage></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Telenti</surname><given-names>A</given-names></name><name><surname>Imboden</surname><given-names>P</given-names></name><name><surname>Marchesi</surname><given-names>F</given-names></name><name><surname>Schmidheini</surname><given-names>T</given-names></name><name><surname>Bodmer</surname><given-names>T</given-names></name></person-group><article-title>Direct automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis</article-title><source>Antimicrob Agents Chemother</source><year>1993</year><fpage>2054</fpage><lpage>2058</lpage><pub-id pub-id-type="pmid">8257122</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapur</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>LL</given-names></name><name><surname>Iordanescu</surname><given-names>S</given-names></name><name><surname>Hamrick</surname><given-names>M</given-names></name><name><surname>Wanger</surname><given-names>BN</given-names></name><name><surname>Mooser</surname><given-names>JM</given-names></name></person-group><article-title>Characterization by automated DNA sequencing of mutations in the gene rpoB encoding the RNA polymerase B subunit in rifampin resistant Mycobacterium tuberculosis strains from New York City and Texas</article-title><source>J Clin Microbiol</source><year>1994</year><fpage>1095</fpage><lpage>1098</lpage><pub-id pub-id-type="pmid">8027320</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Katsukawa</surname><given-names>C</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Yin</surname><given-names>YP</given-names></name><name><surname>Tasaka</surname><given-names>H</given-names></name><name><surname>Ueda</surname><given-names>N</given-names></name><name><surname>Makino</surname><given-names>M</given-names></name></person-group><article-title>Mutations in rpoB gene of rifampicine resistant clinical isolates of Mycobacterium tuberculosis in Japan</article-title><source>Kansenshogaku Zasshi</source><year>1995</year><volume>69</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">7751750</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohno</surname><given-names>H</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name><name><surname>Kohno</surname><given-names>S</given-names></name><name><surname>Tashiro</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name></person-group><article-title>Relationship between rifampin MICs and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan</article-title><source>Antimicrob Agents Chemother</source><year>1996</year><fpage>1053</fpage><lpage>1056</lpage><pub-id pub-id-type="pmid">8849230</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lilly</surname><given-names>K</given-names></name><name><surname>Yuen</surname><given-names>W</given-names></name><name><surname>David</surname><given-names>L</given-names></name><name><surname>Peter</surname><given-names>JC</given-names></name></person-group><article-title>Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia</article-title><source>J Clin Microbiol</source><year>1999</year><fpage>3844</fpage><lpage>3850</lpage><pub-id pub-id-type="pmid">10565894</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>C</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name></person-group><article-title>Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay</article-title><source>J Clin Microbiol</source><year>1997</year><fpage>2663</fpage><lpage>2666</lpage><pub-id pub-id-type="pmid">9316929</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spindola de Miranda</surname><given-names>S</given-names></name><name><surname>Kritski</surname><given-names>A</given-names></name><name><surname>Filliol</surname><given-names>I</given-names></name><name><surname>Mabilat</surname><given-names>C</given-names></name><name><surname>Panteix</surname><given-names>G</given-names></name><name><surname>Drouet</surname><given-names>E</given-names></name></person-group><article-title>Mutations in the rpoB gene of rifampin resistant Mycobacterium tuberculosis strains isolated in Brazil and France</article-title><source>Mem Inst Oswaldo Cruz</source><year>2001</year><fpage>247</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">11285505</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China</article-title><source>J Clinic Microbiol</source><year>2003</year><volume>41</volume><fpage>2209</fpage><lpage>2212</lpage><pub-id pub-id-type="doi">10.1128/JCM.41.5.2209-2212.2003</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Soolingen</surname><given-names>D</given-names></name><name><surname>de Haas</surname><given-names>PEW</given-names></name><name><surname>van Doorn</surname><given-names>HR</given-names></name><name><surname>Kuijper</surname><given-names>E</given-names></name><name><surname>Rinder</surname><given-names>H</given-names></name><name><surname>Borgdorff</surname><given-names>MW</given-names></name></person-group><article-title>Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands</article-title><source>J Infect Dis</source><year>2000</year><fpage>1788</fpage><lpage>1790</lpage><pub-id pub-id-type="pmid">11069256</pub-id><pub-id pub-id-type="doi">10.1086/317598</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khamis</surname><given-names>N</given-names></name><name><surname>Amin</surname><given-names>MM</given-names></name><name><surname>Zagloul</surname><given-names>MZ</given-names></name><name><surname>Girgis</surname><given-names>SA</given-names></name><name><surname>Shetta</surname><given-names>M</given-names></name></person-group><article-title>DNA sequencing and bacteriophage based technique for rapid detection of rifampicine resistant Mycobacterium tuberculosis</article-title><source>Egypt J Med Lab Sci (ESIC)</source><year>2004</year><volume>13</volume><fpage>28</fpage><lpage>36</lpage></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mokrousov</surname><given-names>I</given-names></name><name><surname>Narvskaya</surname><given-names>O</given-names></name><name><surname>Otten</surname><given-names>T</given-names></name><name><surname>Limeschenko</surname><given-names>E</given-names></name><name><surname>Steklova</surname><given-names>L</given-names></name><name><surname>Vyshnevskiy</surname><given-names>B</given-names></name></person-group><article-title>High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from north-western Russia, 1996 to 2001</article-title><source>Antimicrob Agents Chemother</source><year>2002</year><fpage>1417</fpage><lpage>1424</lpage><pub-id pub-id-type="pmid">11959577</pub-id><pub-id pub-id-type="doi">10.1128/AAC.46.5.1417-1424.2002</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>YN</given-names></name><name><surname>Ge</surname><given-names>CR</given-names></name></person-group><article-title>Rapid screening of katG gene mutation in isoniazid-resistant Mycobacterium tuberculosis</article-title><source>Zhejiang Da Xue Xue Bao Yi Xue Ban</source><year>2002</year><volume>31</volume><fpage>178</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">12596308</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martilla</surname><given-names>JH</given-names></name><name><surname>Soini</surname><given-names>E</given-names></name><name><surname>Erola</surname><given-names>E</given-names></name><name><surname>Otten</surname><given-names>AV</given-names></name><name><surname>Vasilyef</surname><given-names/></name><name><surname>Viljanen</surname><given-names>MK</given-names></name></person-group><article-title>A Ser315Thr substitution in katG is predominant in genetically heterogenous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia</article-title><source>Antimicrob Agents Chemother</source><year>1998</year><fpage>2443</fpage><lpage>2445</lpage><pub-id pub-id-type="pmid">9736581</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Fares</surname><given-names>E</given-names></name><name><surname>Araj</surname><given-names>GF</given-names></name><name><surname>Chugh</surname><given-names>TD</given-names></name><name><surname>Mustafa</surname><given-names>AS</given-names></name></person-group><article-title>Prevalence of S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Dubai and Beirut</article-title><source>Inter J Tuber and lung dis</source><year>2002</year><volume>6</volume><fpage>920</fpage><lpage>926</lpage></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Jaber</surname><given-names>AA</given-names></name><name><surname>Mokaddas</surname><given-names>E</given-names></name></person-group><article-title>Frequency of embB codon 306 mutations in ethambutol-susceptible and resistant clinical Mycobacterium tuberculosis isolates in Kuwait</article-title><source>Tuberculosis</source><year>2007</year><volume>87</volume><fpage>123</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17289435</pub-id><pub-id pub-id-type="doi">10.1016/j.tube.2006.05.004</pub-id></citation></ref></ref-list></back></article>


